THL signs $2.5bn takeover deal for US healthtech company Agiliti
Upon completion of the deal, Agiliti will become a private company and no longer be publicly listed/traded on the New York Stock Exchange (NYSE).
27 February 2024
27 February 2024
Upon completion of the deal, Agiliti will become a private company and no longer be publicly listed/traded on the New York Stock Exchange (NYSE).
The positive blood culture (PBC) Separator with Selux AST System allows laboratories to conduct tests directly from positive blood cultures.
The collaboration extends to seeking approvals from the Centers for Medicare & Medicaid Services (CMS) for coding, billing and reimbursement processes.
Akili’s digital therapeutic EndeavorRx has been approved by the the US Food and Drug Administration (FDA) to treat paediatric patients with attention deficit hyperactivity disorder (ADHD).
IceCure’s ProSense system is a minimally invasive cryoablation technology that destroys tumours by freezing, instead of surgical removal.
Natera’s molecular residual disease test Signatera is covered for ovarian and breast cancer indications.
The capsule sponge test is transforming the diagnosis of Barrett's oesophagus, reducing invasive procedures and saving costs.
The study will evaluate the AeriSeal System's ability to limit collateral ventilation in patients with severe chronic obstructive pulmonary disease (COPD) or emphysema.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.